NCT06691074

Brief Summary

This study seeks to assess the acute durability of the CTI block when PEF energy is used. Second goal is to establish the optimal waiting time for the conduction recovery after PEF CTI ablation and to assess the utility of routine adenosine testing for dormant conduction. Moreover, this study aims to investigate the differences in acute efficacy and adverse events (hemolysis, coronary vasospasm) between the two available configurations (basket or flower) of the pentaspline Farawave catheter (Farapulse-Boston Scientific Inc, USA).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 16, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

September 16, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

November 15, 2024

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

November 15, 2024

Status Verified

September 1, 2024

Enrollment Period

1.3 years

First QC Date

September 16, 2024

Last Update Submit

November 14, 2024

Conditions

Keywords

Pulsed Electric FieldCavo-tricuspid IsthmusBiderectional Block

Outcome Measures

Primary Outcomes (1)

  • The acute durability of the CTI block

    The primary goal of this study is to assess the acute durability of the CTI block when PEF energy is used. The bidirectional block on the CTI will be demonstrated with standard pacing manoeuvres (differential pacing from duodecapolar catheter and proximal CS).

    During the ablation procedure

Secondary Outcomes (4)

  • The optimal waiting time for the conduction recovery after PEF CTI ablation

    During the procedure

  • The utility of routine adenosine testing for dormant conduction on the CTI

    During the ablation procedure.

  • Concentration of plasma free haemoglobin

    During the ablation procedure

  • The presence of the coronary vasospasm

    During the ablation procedure

Study Arms (2)

Flower configuration

ACTIVE COMPARATOR

Ablation of the CTI using a Farapulse catheter in flower configuration

Procedure: Catheter ablation of cavotricuspid isthmus using flower configuration of the Farapulse catheter

Basket configuration

ACTIVE COMPARATOR

Ablation of the CTI using a Farapulse catheter in basket configuration

Procedure: Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter

Interventions

Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter

Basket configuration

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with paroxysmal AF undergoing PVI by PEF energy with documented typical atrial flutter or patients with persistent AF in whom catheter ablation of CTI is planned as a part of a complex procedure
  • Age ≥ 18 years at the time of study enrollment
  • Signed informed consent

You may not qualify if:

  • \- LA diameter \> 65 mm (measured in the parasternal long-axis view)
  • History of CTI ablation in the past
  • History of cardiac valve surgery
  • Significant valvular defect
  • Age below 18 years
  • Pregnancy, breastfeeding
  • Any disease with a life expectancy \<1 year
  • Uncorrected congenital heart disease or valvular obstruction
  • Active myocarditis
  • Untreated hypothyroidism or hyperthyroidism
  • Recipient of any major organ transplant (e.g., lung, liver, heart)
  • HIV positivity with a survival expectancy of less than five years due to HIV
  • Chronic dialysis treatment
  • Unwillingness to participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute for Clinical and Experimental Medicine

Prague, Prague, 14200, Czechia

RECRUITING

Related Publications (3)

  • Morales G, Darrat YH, Lellouche N, Kim SM, Butt M, Bidwell K, Lippert W, Ogunbayo G, Hamon D, Di Biase L, Natale A, Parrott K, Elayi CS. Use of adenosine to shorten the post ablation waiting period for cavotricuspid isthmus-dependent atrial flutter. J Cardiovasc Electrophysiol. 2017 Aug;28(8):876-881. doi: 10.1111/jce.13233. Epub 2017 May 29.

    PMID: 28429528BACKGROUND
  • Yoneda ZT, Shoemaker MB, Richardson T, Crawford D, Kanagasundram A, Shen S, Estrada JC, Holmes B, Lugo R, McHugh J, Saavedra P, Crossley G 3rd, Ellis CR, Montgomery JA, Michaud GF. Conduction Recovery After Cavotricuspid Isthmus Ablation When Performed With or Without Concomitant Atrial Fibrillation Ablation. JACC Clin Electrophysiol. 2020 Aug;6(8):989-996. doi: 10.1016/j.jacep.2020.04.031.

    PMID: 32819535BACKGROUND
  • Chen J, de Chillou C, Ohm OJ, Hoff PI, Rossvoll O, Andronache M, Sadoul N, Magnin-Poull I, Erga KS, Aliot E. Acute resumption of conduction in the cavotricuspid isthmus after catheter ablation in patients with common atrial flutter. Real-time evaluation and long-term follow-up. Europace. 2002 Jul;4(3):255-63. doi: 10.1053/eupc.2002.0243.

    PMID: 12134971BACKGROUND

MeSH Terms

Conditions

Atrial Flutter

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Doctor

Study Record Dates

First Submitted

September 16, 2024

First Posted

November 15, 2024

Study Start

September 16, 2024

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

November 15, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will share

all IPD collected throughout the trial

Shared Documents
STUDY PROTOCOL, CSR

Locations